A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
ConditionAdvance Solid Tumors
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorKivu Bioscience Inc.
About this trial
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
Eligibility criteria
Qualifiers
Male or female ≥18 years of age
No therapy of proven efficacy exists for the tumor
Pathologically or histologically documented diagnosis of advanced / metastatic solid tumor malignancy that is resistant to standard therapy or for which no standard therapy is available.
Adequate bone marrow, kidney, and liver function
Disqualifiers
Prior treatment with any ADC with topoisomerase 1 inhibitor payload
Any PTK7 - targeted therapy
Uncontrolled cardiovascular disease
Active Hepatitis B, Hepatitis C, or HIV infection
Trial design
Treatments tested in this trial
- KIVU-107
Treatment groups
76 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov